Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Immune biologics including TNF-alpha inhibitors are among the most commercially successful biopharmaceutical products and therefore offer a great opportunity for biosimilars developers. The pipeline of immune biosimilars includes several agents that reference AbbVie’s lucrative biologic Humira (adalimumab), which are available in Europe in October 2018, and biosimilars referencing Roche’s Rituxan/MabThera, which have already launched in Europe and are set to launch in the United States in Q3 2019. As the immune biosimilars space becomes increasingly competitive, it is important that manufacturers/marketers of biosimilars and branded biologics understand which factors influence physicians’ uptake. Decision Resources Group has conducted market research with rheumatologists and gastroenterologists in France, Germany, and the United States to gain insights on physicians’ attitudes toward biosimilars, the drivers and barriers to biosimilar use, and the expectations for biosimilar adoption.
Key companies mentioned:
Key drugs mentioned:
Already a Client? Log in to access this report.
Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.